💊 Aurobindo Pharma's US Arm Gets FTC Approval for $250 Million Lannett Acquisition

Aurobindo Pharma USA**, a wholly owned subsidiary of **Aurobindo Pharma**, has received approval from the U.S. Federal Trade Commission (FTC) to proceed with the acquisition of **Lannett Company LLC**. The deal, valued at **$250 million**, is expected to close before the end of June 2026. ## 📌 Key Highlights ✅ **Transaction Value:** $250 million (cash-free, debt-free basis) ✅ **Target Company:** Lannett Company LLC, a Pennsylvania-based generic pharmaceutical company ✅ **Manufacturing Boost:** Adds Lannett's Seymour, Indiana facility with capacity of nearly **4 billion doses annually** ✅ **Strategic Expansion:** Strengthens Aurobindo's presence in complex, non-opioid controlled substances ✅ **Financial Impact:** Expected to be immediately accretive to earnings per share (EPS) ✅ **Synergy Benefits:** Cost efficiencies, SG&A synergies and operational integration advantages ## 🔍 Strategic Significance The acquisition enhances Aurobindo's U.S. manufacturing footprint and aligns with ongoing efforts to strengthen domestic pharmaceutical supply chains. It also provides access to Lannett's differentiated pipeline of complex generic products, supporting long-term growth. ## 📈 Why Investors Should Watch * Expands product portfolio in higher-value generic segments. * Increases manufacturing capabilities in the U.S. * Expected to deliver immediate earnings accretion. * Creates opportunities for operational and cost synergies. * Supports sustainable long-term growth through pipeline expansion. **Like, Follow & Share** 🔔 *Disclaimer: This post is for informational and educational purposes only and should not be construed as investment advice. $AUROPHARMA